Tolerance of half-body irradiation as systemic therapy for patients with locally advanced breast cancer.
BACKGROUND
Locally advanced breast cancer (LABC) is one of the main causes of cancer death among women in Bulgaria. In 1988, when this study started, there was still controversy about the role of chemotherapy in controlling systemic disease. There were encouraging results from the Radiation Therapy Oncology Group (RTOG) 82-06 study suggesting that half-body irradiation (HBI) should be used earlier in the disease course to prevent the development of metastases. There were many patients with LABC requiring treatment, but there was a problem with obtaining the drugs needed; they were expensive and not consistently available.


METHODS
Taking into account the medical contraindications to chemo-therapy treatment, its toxicity, and the possibility of chemoresistance, we initiated this study to look at the effects of HBI given as two fractions of 4 Gy to the upper and then lower parts of the body, after surgery and before local radiotherapy.


RESULTS
The acute tolerance of this regimen in 36 patients with LABC was as good as it was in 4 additional LABC patients with M1 disease, and hematologic recovery was satisfactory.


CONCLUSIONS
We conclude that systemic treatment with HBI is tolerable. It therefore may be a convenient and cost-effective treatment for LABC, although better treatments are still needed.
Gocheva
L
L
Radiotherapy Department, Medical University, Sofia, Bulgaria. r.petkov@bgcict.acad.bg
Todorov
J
J
Danon
S
S
D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D018567:Breast Neoplasms, Male / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D004906:Erythrocyte Count / Q000528:radiation effects; D005260:Female; D005500:Follow-Up Studies; D017619:Hemibody Irradiation / Q000009:adverse effects; D006801:Humans; D007958:Leukocyte Count / Q000528:radiation effects; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000209:etiology; D011014:Pneumonia / Q000209:etiology; D012008:Recurrence; D015996:Survival Rate